Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV Cohort study

被引：203

作者：

Rauch, A.

Nolan, D.

Martin, A.

McKinnon, E.

Almeida, C.

Mallal, Simon

机构：

[1] Ctr Clin Immunol & Biomed Stat, Perth, WA, Australia

[2] Univ Hosp Bern, Div Infect Dis, CH-3010 Bern, Switzerland

来源：

CLINICAL INFECTIOUS DISEASES | 2006年 / 43卷 / 01期

基金：

英国医学研究理事会;

关键词：

D O I：

10.1086/504874

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Abacavir therapy is associated with significant drug hypersensitivity in similar to 8% of recipients, with retrospective studies indicating a strong genetic association with the HLA-B*5701 allelle. In this prospective study, involving 260 abacavir-naive individuals ( 7.7% of whom were positive for HLA-B*5701), we confirm the usefulness of genetic risk stratification, with no cases of abacavir hypersensitivity among 148 HLA-B*5701 negative recipients.

引用

收藏

页码：99 / 102

页数：4

相关论文

共 11 条

[1] Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir [J].

Cutrell, AG ;

Hernandez, JE ;

Fleming, JW ;

Edwards, MT ;

Moore, MA ;

Brothers, CH ;

Scott, TR .

ANNALS OF PHARMACOTHERAPY, 2004, 38 (12) :2171-2172

[2] Abacavir plus lamivuldine - A review of their combined use in the management of HIV infection [J].

Dando, TM ;

Scott, LJ .

DRUGS, 2005, 65 (02) :285-302

[3]

Easterbrook P J, 2003, HIV Med, V4, P321, DOI 10.1046/j.1468-1293.2003.00166.x

[4] Genetic variations in HLA-B region and hypersensitivity reactions to abacavir [J].

Hetherington, S ;

Hughes, AR ;

Mosteller, M ;

Shortino, D ;

Baker, KL ;

Spreen, W ;

Lai, E ;

Davies, K ;

Handley, A ;

Dow, DJ ;

Fling, ME ;

Stocum, M ;

Bowman, C ;

Thurmond, LM ;

Roses, AD .

LANCET, 2002, 359 (9312) :1121-1122

[5] Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir [J].

Hetherington, S ;

McGuirk, S ;

Powell, G ;

Cutrell, A ;

Naderer, O ;

Spreen, B ;

Lafon, S ;

Pearce, G ;

Steel, H .

CLINICAL THERAPEUTICS, 2001, 23 (10) :1603-1614

[6] Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations [J].

Hughes, AR ;

Mosteller, M ;

Bansal, AT ;

Davies, K ;

Haneline, SA ;

Lai, EH ;

Nangle, K ;

Scott, T ;

Spreen, WR ;

Warren, LL ;

Roses, AD .

PHARMACOGENOMICS, 2004, 5 (02) :203-211

[7] Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir [J].

Mallal, S ;

Nolan, D ;

Witt, C ;

Masel, G ;

Martin, AM ;

Moore, C ;

Sayer, D ;

Castley, A ;

Mamotte, C ;

Maxwell, D ;

James, I ;

Christiansen, FT .

LANCET, 2002, 359 (9308) :727-732

[8] Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant [J].

Martin, AM ;

Nolan, D ;

Gaudieri, S ;

Almeida, CA ;

Nolan, R ;

James, I ;

Carvalho, F ;

Phillips, E ;

Christiansen, FT ;

Purcell, AW ;

McCluskey, J ;

Mallal, S .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (12) :4180-4185

[9]

Nolan David, 2003, J HIV Ther, V8, P36

[10] Reasons for early abacavir discontinuation in HIV-infected patients [J].

Peyriere, H ;

Guillemin, V ;

Lotthe, A ;

Baillat, V ;

Fabre, J ;

Favier, C .

ANNALS OF PHARMACOTHERAPY, 2003, 37 (10) :1392-1397